Delving into the Latest Updates on Hefei Xingmou Biotechnology Co., Ltd. with Synapse

Overview

Tags

Eye Diseases

Congenital Disorders

Endocrinology and Metabolic Disease

AAV based gene therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	4
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

AAV based gene therapy	9

Top 5 Target	Count

NPY(neuropeptide Y)	1
Ang2 x VEGF	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

4

3

Preclinical

IND Application

1

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

XMVA-09 ( Ang2 x VEGF )	Wet age-related macular degeneration More	Phase 2 Clinical
XM-001	Wet age-related macular degeneration More	IND Application
XM-006	Arthritis More	Preclinical
XM-003	Graves Ophthalmopathy More	Preclinical
XM-002	dry age-related macular degeneration More	Preclinical